Ticker Story
LLY
2 independent context-only signals · 30 days
2 of 8 signal types active in the last 90 days
AI Analysis
LLY is showing convergence across three independent bullish signals—congressional cluster activity, trademark filing activity, and FDA catalyst developments—indicating alignment among distinct fundamental and regulatory signal sources.
Signal Timeline
YIELM — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →YEZZRETA — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →YEZRETA — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →YEZRET — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →VYNNRETA — Pharmaceutical preparations; vaccines for human use
View primary source →RETAHNOVA — Pharmaceutical preparations; vaccines for human use
View primary source →VYNRETA — Pharmaceutical preparations; vaccines for human use
View primary source →HIRETA — Pharmaceutical preparations; vaccines for human use
View primary source →RETAHVERA — Pharmaceutical preparations; vaccines for human use
View primary source →VERAHRETA — Pharmaceutical preparations; vaccines for human use
View primary source →VYMMRETA — Pharmaceutical preparations; vaccines for human use
View primary source →VYMRETA — Pharmaceutical preparations; vaccines for human use
View primary source →Eli Lilly and Company — A Study of Brenipatide in Adult Participants With Major Depressive Disorder
View primary source →LILLY ENDOWMENT, INC. — 13G/A, 9.6% of ELI LILLY AND COMPANY
View primary source →Eli Lilly and Company — A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
View primary source →Eli Lilly and Company — A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
View primary source →Eli Lilly and Company — A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
View primary source →Eli Lilly and Company — A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
View primary source →Eli Lilly and Company — A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
View primary source →Eli Lilly and Company — A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
View primary source →Eli Lilly and Company — A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
View primary source →Eli Lilly and Company — A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
View primary source →Eli Lilly and Company — A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
View primary source →Eli Lilly and Company — A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
View primary source →Eli Lilly and Company — A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
View primary source →Eli Lilly and Company — A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
View primary source →Eli Lilly and Company — A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
View primary source →Eli Lilly and Company — A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
View primary source →Eli Lilly and Company — Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
View primary source →Eli Lilly and Company — A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
View primary source →Eli Lilly and Company — A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
View primary source →Eli Lilly and Company — A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
View primary source →Eli Lilly and Company — A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
View primary source →Eli Lilly and Company — Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
View primary source →Eli Lilly and Company — A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
View primary source →Eli Lilly and Company — A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
View primary source →Eli Lilly and Company — A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
View primary source →Eli Lilly and Company — A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
View primary source →Eli Lilly and Company — A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
View primary source →Eli Lilly and Company — A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
View primary source →Eli Lilly and Company — A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
View primary source →Eli Lilly and Company — A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
View primary source →NEXVOUND — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →SOHENJI — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →IPGUAZU — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →BRAKLAYMA — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →ZAYLAWAI — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →ZAYLAWEI — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →YUZEVNI — Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, a
View primary source →3 members, buy · David J. Taylor, Byron Donalds, Gilbert Cisneros
View primary source →⚠ Detection and context from official public sources — not financial advice, not a prediction.